PTPRC and meningioma: Next, we analysed 42 meningioma samples for both M2 macrophages (CD45+HLA-DR+CD14+CD163+) and tumour cells (CD45−HLA−DR−CD14−CD44+) at Passage 0, and related these results to mutational status.